RADNOR | Jotup

AVANGRID INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Avangrid, Inc. (AGR) and Encourages Investors to Contact the Firm

Retrieved on:

금요일, 5월 10, 2024

PHILADELPHIA, May 09, 2024 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Avangrid, Inc. (NYSE: AGR) on behalf of the company’s shareholders.

Key Points:

PHILADELPHIA, May 09, 2024 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Avangrid, Inc. (NYSE: AGR) on behalf of the company’s shareholders.
The investigation seeks to determine whether Avangrid and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors.
Avangrid shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

목요일, 5월 9, 2024

RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.

Key Points:

ET –
RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.
General and Administrative (G&A) expenses were $4.6 million for the quarter ended March 31, 2024, compared to $2.6 million for the quarter ended March 31, 2023.
Total other income, net was $3.9 million for the quarter ended March 31, 2024, compared to $2.3 million for the quarter ended March 31, 2023.
Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.

GoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Retrieved on:

목요일, 5월 9, 2024

Lead, LLP, GO, News, Risk, PBM, Plasma protein binding, District court, HERE, Defendant, Court, GoodRx, Pharmacy, Cryptocurrency

Important Deadline Reminder: Investors who purchased or otherwise acquired GoodRx common stock during the Class Period may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class.

Key Points:

Important Deadline Reminder: Investors who purchased or otherwise acquired GoodRx common stock during the Class Period may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class.
If you suffered GoodRx losses, you may CLICK HERE or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_m...
You can also contact attorney Jonathan Naji, Esq.
of Kessler Topaz by calling (484) 270-1453 or by email at [email protected] .
Kessler Topaz Meltzer & Check, LLP encourages GoodRx investors who have suffered significant losses to contact the firm directly to acquire more information.

CLASS ACTION NOTICE FOR CC: Kessler Topaz Meltzer & Check, LLP Reminds The Chemours Company Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm

Retrieved on:

목요일, 5월 9, 2024

Lead, CFO, LLP, Annual report, COPY, Collection, Ethics, Controller, Senior, District court, Audit committee, Court, Form 10-K, Adjustment, VIEW, CC, Cryptocurrency

This action, captioned Taylor Jr. v. The Chemours Company, et al., Case No.

Key Points:

This action, captioned Taylor Jr. v. The Chemours Company, et al., Case No.
YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/the-chemours-company?utm_campaign=cc&mktm=r
CANNOT VIEW THIS VIDEO?
Prior to and during the Class Period, Chemours also set and publicized certain criteria for executive compensation.
Kessler Topaz Meltzer & Check, LLP encourages Chemours investors who have suffered significant losses to contact the firm directly to acquire more information.

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Retrieved on:

월요일, 5월 6, 2024

CKD, Therapy, Chronic kidney disease, Bank, Conference, Hypertension

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.

Key Points:

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
Bank of America Securities Health Care Conference:

Doximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Retrieved on:

월요일, 5월 6, 2024

Lead, LLP, COVID, News, Division of Tangney, Research, Growth, District court, HERE, Court, THIS, Workforce

Important Deadline Reminder: Investors who purchased or otherwise acquired Doximity common stock during the Class Period may, no later than June 17, 2024, move the Court to serve as lead plaintiff for the class.

Key Points:

Important Deadline Reminder: Investors who purchased or otherwise acquired Doximity common stock during the Class Period may, no later than June 17, 2024, move the Court to serve as lead plaintiff for the class.
If you suffered Doximity losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/doximity-inc?utm_source=PR&utm_medium=lin...
You can also contact attorney Jonathan Naji, Esq.
of Kessler Topaz by calling (484) 270-1453 or by email at [email protected] .
Kessler Topaz Meltzer & Check, LLP encourages Doximity investors who have suffered significant losses to contact the firm directly to acquire more information.

Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc.

Retrieved on:

일요일, 5월 5, 2024

Sale, FDA, Lead, Cirrhosis, Fatty liver disease, LLP, EFX, News, NASH, 8-K, District court, HERE, Patient, Non-alcoholic fatty liver disease, Histology, Fibrosis, Drug development, Therapy, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
You can also contact attorney Jonathan Naji, Esq.
Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

VSTS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Vestis Corporation (NYSE: VSTS) Investors with Losses to Contact the Firm

Retrieved on:

일요일, 5월 5, 2024

LLP, Government, VSTS, News, EPS

RADNOR, Pa., May 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Vestis Corporation (NYSE: VSTS) (“Vestis”).

Key Points:

RADNOR, Pa., May 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Vestis Corporation (NYSE: VSTS) (“Vestis”).
If you are a Vestis investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq.
For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com .
Kessler Topaz Meltzer & Check, LLP

GoodRx Holdings, Inc. (GDRX) Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Retrieved on:

토요일, 5월 4, 2024

Lead, LLP, GO, News, Risk, PBM, Plasma protein binding, District court, HERE, Defendant, Court, GoodRx, Pharmacy, Cryptocurrency

Important Deadline Reminder: Investors who purchased or otherwise acquired GoodRx common stock during the Class Period may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class.

Key Points:

Important Deadline Reminder: Investors who purchased or otherwise acquired GoodRx common stock during the Class Period may, no later than June 21, 2024, move the Court to serve as lead plaintiff for the class.
If you suffered GoodRx losses, you may CLICK HERE or GO TO: https://www.ktmc.com/new-cases/goodrx-holdings-inc-1?utm_source=PR&utm_m...
You can also contact attorney Jonathan Naji, Esq.
of Kessler Topaz by calling (484) 270-1453 or by email at [email protected] .
Kessler Topaz Meltzer & Check, LLP encourages GoodRx investors who have suffered significant losses to contact the firm directly to acquire more information.

NASDAQ: ADSK: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Autodesk, Inc.

Retrieved on:

토요일, 5월 4, 2024

Lead, LLP, News, District court, HERE, ADSK, E pluribus unum, Annual report, Fraud, Disclosure, Telescopic sight

The action charges Autodesk with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points:

The action charges Autodesk with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of Autodesk’s materially misleading statements and omissions to the public, Autodesk’s investors have suffered significant losses.
If you suffered Autodesk losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/autodesk-inc?utm_source=PR&utm_medium=lin...
You can also contact attorney Jonathan Naji, Esq.
Kessler Topaz Meltzer & Check, LLP encourages Autodesk investors who have suffered significant losses to contact the firm directly to acquire more information.